Format

Send to

Choose Destination
Minerva Pediatr. 2019 Jun;71(3):253-262. doi: 10.23736/S0026-4946.19.05526-9.

Should we treat every infant with a probiotic?

Author information

1
Division of Neonatology, University of California Davis, Sacramento, CA, USA - munderwood@ucdavis.edu.

Abstract

Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of probiotics in infantile colic is strong but limited to the L. reuteri DSM 17938 strain and to breast-fed infants. The evidence for prevention of atopic dermatitis is mixed with the strongest benefit seen with initiation of probiotic treatment during pregnancy and continued after birth. The more provocative question of whether routine administration of probiotics to all infants can reverse trends in intestinal dysbiosis and dysbiosis-associated diseases remains unanswered. A large cohort study or randomized controlled trial of probiotics in infancy with sufficient follow-up to assess changes in dysbiosis-associated diseases is warranted and could be paradigm shifting.

PMID:
31017382
DOI:
10.23736/S0026-4946.19.05526-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center